Diarylquinolines target subunit c of mycobacterial ATP synthase
Faculty of Pharmaceutical, Biomedical and Veterinary Sciences. Pharmacy
New York :Nature Publishing Group
Nature chemical biology. - New York
, p. 323-324
University of Antwerp
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.